Incidence and risk factors for persistent symptoms in adults previously hospitalized for COVID-19.
COVID-19
PASC
asthma
long COVID
post-COVID Condition
post-COVID Syndrome
postacute sequelae SARS-CoV-2 infection
risk factors
Journal
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
ISSN: 1365-2222
Titre abrégé: Clin Exp Allergy
Pays: England
ID NLM: 8906443
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
07
06
2021
accepted:
24
07
2021
pubmed:
6
8
2021
medline:
14
9
2021
entrez:
5
8
2021
Statut:
ppublish
Résumé
The long-term sequalae of COVID-19 remain poorly characterized. We assessed persistent symptoms in previously hospitalized patients with COVID-19 and assessed potential risk factors. Data were collected from patients discharged from 4 hospitals in Moscow, Russia between 8 April and 10 July 2020. Participants were interviewed via telephone using an ISARIC Long-term Follow-up Study questionnaire. 2,649 of 4755 (56%) discharged patients were successfully evaluated, at median 218 (IQR 200, 236) days post-discharge. COVID-19 diagnosis was clinical in 1291 and molecular in 1358. Most cases were mild, but 902 (34%) required supplemental oxygen and 68 (2.6%) needed ventilatory support. Median age was 56 years (IQR 46, 66) and 1,353 (51.1%) were women. Persistent symptoms were reported by 1247 (47.1%) participants, with fatigue (21.2%), shortness of breath (14.5%) and forgetfulness (9.1%) the most common symptoms and chronic fatigue (25%) and respiratory (17.2%) the most common symptom categories. Female sex was associated with any persistent symptom category OR 1.83 (95% CI 1.55 to 2.17) with association being strongest for dermatological (3.26, 2.36 to 4.57) symptoms. Asthma and chronic pulmonary disease were not associated with persistent symptoms overall, but asthma was associated with neurological (1.95, 1.25 to 2.98) and mood and behavioural changes (2.02, 1.24 to 3.18), and chronic pulmonary disease was associated with chronic fatigue (1.68, 1.21 to 2.32). Almost half of adults admitted to hospital due to COVID-19 reported persistent symptoms 6 to 8 months after discharge. Fatigue and respiratory symptoms were most common, and female sex was associated with persistent symptoms.
Sections du résumé
BACKGROUND
The long-term sequalae of COVID-19 remain poorly characterized. We assessed persistent symptoms in previously hospitalized patients with COVID-19 and assessed potential risk factors.
METHODS
Data were collected from patients discharged from 4 hospitals in Moscow, Russia between 8 April and 10 July 2020. Participants were interviewed via telephone using an ISARIC Long-term Follow-up Study questionnaire.
RESULTS
2,649 of 4755 (56%) discharged patients were successfully evaluated, at median 218 (IQR 200, 236) days post-discharge. COVID-19 diagnosis was clinical in 1291 and molecular in 1358. Most cases were mild, but 902 (34%) required supplemental oxygen and 68 (2.6%) needed ventilatory support. Median age was 56 years (IQR 46, 66) and 1,353 (51.1%) were women. Persistent symptoms were reported by 1247 (47.1%) participants, with fatigue (21.2%), shortness of breath (14.5%) and forgetfulness (9.1%) the most common symptoms and chronic fatigue (25%) and respiratory (17.2%) the most common symptom categories. Female sex was associated with any persistent symptom category OR 1.83 (95% CI 1.55 to 2.17) with association being strongest for dermatological (3.26, 2.36 to 4.57) symptoms. Asthma and chronic pulmonary disease were not associated with persistent symptoms overall, but asthma was associated with neurological (1.95, 1.25 to 2.98) and mood and behavioural changes (2.02, 1.24 to 3.18), and chronic pulmonary disease was associated with chronic fatigue (1.68, 1.21 to 2.32).
CONCLUSIONS
Almost half of adults admitted to hospital due to COVID-19 reported persistent symptoms 6 to 8 months after discharge. Fatigue and respiratory symptoms were most common, and female sex was associated with persistent symptoms.
Identifiants
pubmed: 34351016
doi: 10.1111/cea.13997
pmc: PMC8444748
doi:
Types de publication
Clinical Trial
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1107-1120Subventions
Organisme : Medical Research Council
ID : MC_PC_19026
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_19059
Pays : United Kingdom
Organisme : UK Embassy in Moscow
ID : INT 2021/RSM C 19 01
Organisme : Medical Research Council
ID : MC_UU_12014/8
Pays : United Kingdom
Organisme : Russian Foundation for Basic Research
ID : 20-04-60063
Investigateurs
Elina Abdeeva
(E)
Nikol Alekseeva
(N)
Elena Antsiferova
(E)
Elena Artigas
(E)
Anastasiia Bairashevskaia
(A)
Anna Belkina
(A)
Vadim Bezrukov
(V)
Semyon Bordyugov
(S)
Maria Bratukhina
(M)
Jessica Chen
(J)
Salima Deunezhewa
(S)
Khalisa Elifkhanova
(K)
Anastasia Ezhova
(A)
Yulia Filippova
(Y)
Aleksandra Frolova
(A)
Julia Ganieva
(J)
Anastasia Gorina
(A)
Yulia Kalan
(Y)
Bogdan Kirillov
(B)
Mariia Korgunova
(M)
Alexandra Krupina
(A)
Anna Kuznetsova
(A)
Ekaterina Listovskaia
(E)
Margarita Mikheeva
(M)
Aigun Mursalova
(A)
Marina Ogandzhanova
(M)
Callum Parr
(C)
Mikhail Rumyantsev
(M)
Denis Smirnov
(D)
Nataliya Shishkina
(N)
Yasmin El-Taravi
(Y)
Maria Varaksina
(M)
Maria Vodianova
(M)
Anna Zezyulina
(A)
Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
EClinicalMedicine. 2021 Aug;38:101019
pubmed: 34308300
BMJ. 2020 Aug 11;370:m3026
pubmed: 32784198
Nat Med. 2021 Apr;27(4):626-631
pubmed: 33692530
Clin Exp Allergy. 2021 Sep;51(9):1107-1120
pubmed: 34351016
BMJ. 2021 Mar 31;372:n693
pubmed: 33789877
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
Eur Respir J. 2020 Aug 13;56(2):
pubmed: 32817205
J Neurovirol. 2021 Feb;27(1):154-159
pubmed: 33528827
Lancet Reg Health Eur. 2021 Jul;6:100122
pubmed: 34027514
Respir Med. 2009 Feb;103(2):216-23
pubmed: 19027278
J Med Virol. 2020 Oct;92(10):1915-1921
pubmed: 32293753
Int J Infect Dis. 2020 Nov;100:327-332
pubmed: 32920235
Nat Med. 2020 Dec;26(12):1803
pubmed: 33288947
Thorax. 2021 Apr;76(4):399-401
pubmed: 33273026
BMJ. 2021 Feb 10;372:n405
pubmed: 33568362
Lancet. 2021 Jan 16;397(10270):220-232
pubmed: 33428867
Nature. 2021 Jun;594(7862):259-264
pubmed: 33887749
J Allergy Clin Immunol Pract. 2021 Mar;9(3):1152-1162.e3
pubmed: 33495097
JAMA. 2020 Aug 11;324(6):603-605
pubmed: 32644129
Allergy. 2020 Oct;75(10):2703-2704
pubmed: 32455491
Clin Infect Dis. 2021 Jul 1;73(1):1-11
pubmed: 33035307
Infection. 2021 Jun 25;:
pubmed: 34170486
Lancet. 2020 Dec 12;396(10266):1861
pubmed: 33308453
BMJ. 2020 May 22;369:m1985
pubmed: 32444460